To study improvement in patients with Obsessive Compulsive Disorder with add-on Intravenous Ketamine vs placebo
Phase 4
- Conditions
- Health Condition 1: F422- Mixed obsessional thoughts and acts
- Registration Number
- CTRI/2024/02/062696
- Lead Sponsor
- Aashi Srivastava
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with Obsessive Compulsive Disorder according to ICD-10 and having Y-BOCS score more than 16
Duration more than 6 months with one failed trial of either SSRI or Clomipramine
Patients who give their consent
Exclusion Criteria
Patients who do not give their informed consent.
Patients with present diagnosis of cardiovascular disorders, glaucoma, raised intracranial pressure and history of head trauma
Pregnant and lactating females
Patients with current diagnosis of schizophrenia
Patients diagnosed with Mental Retardation
Patients having hypersensitivity to ketamine
Patients with diagnosis of severe depression
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of intravenous Ketamine in reducing the intensity of Obsessive Compulsive Symptoms within two weeks of administrationTimepoint: To assess the effect of intravenous Ketamine in reducing the intensity of Obsessive Compulsive Symptoms <br/ ><br> <br/ ><br>First assessment at baseline, then on every third day after receiving the infusion (day 0,day 3,day 6,day 9,day 12,day 15) <br/ ><br>Then weekly assessment for 4 weeks
- Secondary Outcome Measures
Name Time Method To assess phenomenological characteristics which favour response to Ketamine <br/ ><br>To assess safety of administration and Adverse Drug Reaction following KetamineTimepoint: To Follow up patient using side effect checklist